Interest of EMDR (Eye Movement Desensitization and Reprocessing) Psychotherapy in the Management of Schizophrenic Disorders
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Schizophrenic Disorders
- Sponsor
- Hôpital NOVO
- Enrollment
- 6
- Locations
- 2
- Primary Endpoint
- Assessment of the decrease in the severity of positive or negative symptoms of schizophrenia
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.
Detailed Description
Since 2015 more and more studies conducted by researchers, especially Dutch and English, are interested in the use of EMDR (Eye Movement Desensitization and Reprocessing) for other pathologies such as bipolar disorder, unipolar depression, anxiety disorders, psychotic disorders, substance use disorders and chronic pain. These studies show that EMDR appears to be a technique that is both effective, capable of significantly improving symptoms, and without risk for patients, while respecting the protocol and the clinical stabilization provided during the procedure. To date, the use of EMDR for the management of psychotic patients has not been the subject of any prospective study in France and the authors' conclusions converge on the fact that it is essential to carry out more research on the subject. For this, the investigators wish to evaluate the effect of EMDR on the management of patients with schizophrenic disorders, on the basis that this psychotherapy would improve their quality of life (improvement of all the specific scores used in psychiatry). : PANSS, DES, HAD and WEMWBS scales). Finally, the investigators believe that it is relevant to assess the benefit of EMDR six months after hospitalization of patients, in order to measure the maintenance of this efficacy in the medium term
Investigators
Eligibility Criteria
Inclusion Criteria
- •≥ 18 years and over,
- •Hospitalized for decompensated psychotic disorder, Positive diagnosis of schizophrenia or schizoaffective disorder (according to the DSM-V psychiatry manual),
- •With positive or negative symptoms according to the Positive and Negative Syndrome Scale (PANSS),
- •Stabilized clinical condition (considered compatible with hospital discharge),
- •With ambulatory follow-up planned after hospitalization
Exclusion Criteria
- •\< 18 years,
- •Patients who do not meet the diagnostic criteria (according to the DSM-V psychiatry manual) for schizophrenic or schizoaffective disorder),
- •Non-French speaking or illiterate patients,
- •Cognitive disorders making it impossible the understanding and the none- opposition to the study,
- •Non-stabilized clinical condition (incompatible with hospital discharge),
Outcomes
Primary Outcomes
Assessment of the decrease in the severity of positive or negative symptoms of schizophrenia
Time Frame: At 6 month after Hospital discharge (M0)
The decrease in the severity of positive or negative symptoms of schizophrenia is assessed using the "Positive and Negative Syndrome Scale" (PANSS) between M0 and M6.This decrease will be considered effective if it's greater than or equal to 20%.
Secondary Outcomes
- Assessment of the decrease in the intensity of anxiety and depressive symptoms.(At 6 month after Hospital discharge (M0))
- Assessment of the decrease in the intensity of dissociative symptoms.(At 6 month after Hospital discharge (M0))
- Quality of life assessment(At 6 month after Hospital discharge (M0))